Systemic sclerosis (SSc), also known as scleroderma, is a rare chronic connective tissue disease
Pulmonary fibrosis, or fibrosing interstitial lung disease (ILD), is a key driver of mortality in people living with SSc and constitutes a high unmet need1,2
Improving the lives of people living with pulmonary fibrosis is a key focus for Boehringer Ingelheim
INGELHEIM, Germany -- (BUSINESS WIRE) --
Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and EMA. Nintedanib as an anti-fibrotic medicine is already approved in more than 70 countries for the treatment of patients living with idiopathic pulmonary fibrosis (IPF).
Systemic sclerosis, also known as scleroderma, is a rare disease characterised by thickening and scarring of connective tissue throughout the body.1,2 The disease can cause scarring of the skin, lungs (interstitial lung disease), heart and kidneys which can be debilitating and may become life-threatening.1,2 Approximately 25% of patients develop significant pulmonary involvement within three years of diagnosis.3 Lung involvement is the leading cause of death among people with systemic sclerosis.1
Dr. Susanne Stowasser, Associate Head of Respiratory Medicine at Boehringer Ingelheim said, “Systemic sclerosis associated interstitial lung disease has a devastating impact on those it affects – often women in the prime of their lives. Pulmonary fibrosis is a key driver of mortality in systemic sclerosis, and currently there are no approved treatments for SSc-ILD. Boehringer Ingelheim is pleased that we are able to take a step closer to potentially bringing an approved treatment for addressing the decline in lung function to patients with this rare condition.”
The regulatory submissions are part of Boehringer Ingelheim’s ongoing commitment to improving the lives of people living with pulmonary fibrosis, in particular those affected by rare diseases with a high level of unmet need.
Clinical research results relating to nintedanib in SSc-ILD will be shared with the scientific community during the American Thoracic Society Congress (17-22 May).
~ENDS~
Alsym Energy宣布获得新一轮7800万美元融资
GrAI Matter Labs融资1,400万美元
银河娱乐集团再度闪耀米其林星榜
智原推出Low-DPPM通用方案 满足各领域
沙迦向黎巴嫩Amel International颁发
以信心面对癌症:全球调研显示Look
宝洁聚焦“用爱指引”的2020东京奥运会参赛运
“恶意提起知识产权诉讼行为的法律规制”主题
Miura Co在日本推出使用Ceres Power技术
优脍国际集团完成730万美元A轮融资
百名企业家共唱红歌庆祝中国共产党成立100周
迈动互联阳光城集团打造社区电商数据中台
国际内容市场SPP 2021将于7月12日至30日在线上举
T0-T8的文明与科技-- part 2
必维集团推出电动汽车充电站(EVCS)端到端解决方
三星资产运用株式会社选择ICE数据指数用于涵盖
热烈祝贺华翼云财税管控工具应用平台联合并购
中智全球和健康益友宣布战略合作伙伴关系
葡萄酒市场重磅新闻:斯旺河天鹅葡萄酒强势进
AlbaCore Confirms 1.5bn AUM1
Veeva携手生命科学界,为全行业提供众多公司和
中秘传媒盘点那些年抖音的热门商品!
Transphorm获得National
亚马逊商品销量在这个假日季再度刷新纪录